Skip to main content
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: Clin Cancer Res. 2015 Feb 3;21(9):2065–2074. doi: 10.1158/1078-0432.CCR-14-2993

Table 3.

PTEN by ER/PR status

Trial PTEN ER− and PR− ER+ and/or PR+
BCIRG 006
n = 1201
HER2 amplified		 Absent in tumor 35 (6.4%) 30 (4.6%)
Weak in tumor 52 (9.5%) 33 (5.1%)
Weak overall 257 (46.9%) 244 (37.4%)
Moderate overall 184 (33.6%) 302 (46.2%)
Strong in tumor 20 (3.6%) 44 (6.7%)
Total 548 (100%) 653 (100%)
BCIRG 005
n = 1163
HER2 not amplified		 Absent in tumor 86 (35.1%) 99 (10.8%)
Weak in tumor 28 (11.4%) 60 (6.5%)
Weak overall 76 (31.0%) 367 (40.0%)
Moderate overall 43 (17.6%) 344 (37.5%)
Strong in tumor 12 (4.9%) 48 (5.2%)
Total 245 (100%) 918 (100%)